Global Overactive Bladder Treatment Market Growth (Status and Outlook) 2023-2029
Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.
LPI (LP Information)' newest research report, the “Overactive Bladder Treatment Industry Forecast” looks at past sales and reviews total world Overactive Bladder Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Overactive Bladder Treatment sales for 2023 through 2029. With Overactive Bladder Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Overactive Bladder Treatment industry.
This Insight Report provides a comprehensive analysis of the global Overactive Bladder Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Overactive Bladder Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Overactive Bladder Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Overactive Bladder Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Overactive Bladder Treatment.
The global Overactive Bladder Treatment market size is projected to grow from US$ 4989.1 million in 2022 to US$ 6182.8 million in 2029; it is expected to grow at a CAGR of 3.1% from 2023 to 2029.
Global Overactive Bladder Treatment key players include Allergan, Astellas Pharma, Pfizer, Johnson & Johnson, Medtronic, etc. Global top five manufacturers hold a share about 90%. United States is the largest market, with a share about 60%, followed by Europe, with a share about 15 percent. In terms of product, Drugs is the largest segment, with a share about 95%. And in terms of application, the largest application is Idiopathic Overactive Bladder, followed by Neurogenic Overactive Bladder.
This report presents a comprehensive overview, market shares, and growth opportunities of Overactive Bladder Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Drugs
Device
Segmentation by application
Idiopathic Overactive Bladder
Neurogenic Overactive Bladder
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan
Astellas Pharma
Pfizer
Johnson & Johnson
Medtronic
KYORIN Pharmaceutical
Please note: The report will take approximately 2 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook